Please provide your email address to receive an email when new articles are posted on . Teriparatide therapy significantly increased hip and spine bone mineral density and estimated bone strength in ...

In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically ...

This sets us apart in a market where many competitors rely on overseas production. Overall, we believe this milestone underscores our commitment to domestic innovation, rigorous quality standards, and ...

Please provide your email address to receive an email when new articles are posted on . Teriparatide administered through the RT-102 pill provided higher bioavailability than injection with no ...

INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...

PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a ...

SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.

Daily 20-μg and once-weekly 56.5-μg teriparatide (parathyroid hormone 1–34) treatment regimens increase bone mineral density (BMD) and prevent fractures, but changes in bone turnover markers differ ...

Peter Robert Ebeling receives research funding from NHMRC and Eli-Lilly, and honoraria from Eli-Lilly. Teriparatide is an injectable drug to treat severe osteoporosis, a condition where mineral loss ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...